Evidence map›Paper›PMID 42621985›Full record

ArticleMaterials today. Bio2026

Tumor microenvironment-rearranging Nanoassemblies overcome angiogenesis-immunotherapy resistance to potentiate osteosarcoma treatment.

Zili Lin, Qing Liu, Xiangyao Li, Wenlong Wang, Hao Luo, Weiping Xia, Yuhao Yuan, Haibin Zheng, Wei Luo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zili LinDepartment of Orthopaedics, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Qing LiuDepartment of Orthopaedics, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Xiangyao LiDepartment of Orthopaedics, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Wenlong WangDepartment of Breast Surgery, Xiangya Hospital, Central South University, Changsha, 410008, China.
Hao LuoDepartment of Orthopaedics, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Weiping XiaDepartment of Critical Care Medicine, Xiangya Hospital, Central South University, China.
Yuhao YuanDepartment of Orthopaedics, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Haibin ZhengDepartment of Orthopaedics, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Wei LuoDepartment of Orthopaedics, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Conventional anti-angiogenic cancer therapy is frequently undermined by adaptive tumor hypoxia and the consequent establishment of an immunosuppressive microenvironment, which together drive therapeutic resistance. To overcome this limitation, we engineered a tumor-targeted nano-platform (Reg@CeO

Indexed as

Anti-angiogenesisHypoxia mitigationImmunotherapyOsteosarcomaROS clearance

Identifiers

PMID42621985
PMCPMC13488038

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.